Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of Chronocort Versus Cortef in Healthy Male Subjects
NCT03343327Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydrocortisone modified-release in adrenal insufficiency (AI) (2 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Area under the concentration time curve from time 0 to infinity at 24 hours. Started Feb 2018; status: completed.
02
Drugs
hydrocortisone modified-release
03
Conditions
adrenal insufficiency (AI)
Beyond the preview
Go deeper on NCT03343327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343327.